EGFR and neoplasm: In NSCLC, the clinical relevance of the EGFR c.2369C>T p.(Thr790Met) variant at a VAF of 1% in a tumor-rich tissue sample is still under debate, and ultimate therapy decisions by the treating physician need to consider the complete clinical patient context.